Genome Editing Market

SKU: DMBT227 | Last Updated On: Aug 18 2022 | Available Formats

> Genome Editing Market Expected to reach a high CAGR By 2029

Genome Editing Market is segmented By Technology (CRISPR/Cas, TALEN, Zinc Finger Nuclease (ZFN), and Others), By Application (Genetic Engineering (Plant, Animal), Cell Line Engineering, Curing genetic diseases, Drug Discovery and Development, and Others), By End User (Government & Academic Research Institutes, Biotech & Pharmaceutical Companies, and Contract Research Organizations), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Genome Editing Market size is expected to grow at a CAGR during the forecast period (2022-2029). Genome editing is a type of genetic editing where DNA is inserted, deleted, or replaced in the genome of an organism to treat a particular disease using an engineered nuclease or molecular scissors. These nucleases create site-specific double-stranded breaks at desired locations in the genome. The induced double-stranded breaks are repaired through no homologous end joining or homologous recombination resulting in targeted mutations (edits).

Market Dynamics

The global genome editing market growth is driven by the increasing implementation of CRISPR genome editing technology coupled with rising synthetic gene demand in diverse biotechnology domains has primarily driven the market growth over the past few years.  

Extensive use of genome editing in personalized medicine will drive the market growth

Growth in the personalized medicine market is expected to drive the genome editing market. Personalized medicine enables medical practitioners to identify the exact needs of a patient and then prescribe medicines and treatments accordingly. The use of personalized medicine is increasing across the globe, due to its potential for cost-savings, better patient compliance, early detection of diseases, and optimization of therapies. Furthermore, availability of government funding, growth in the number of genomics projects and rise in prevalence of cancer & other genetic disorders will also drive the market growth. In addition, development of CRISPR-based novel diagnostic tools to mitigate adverse impact of the COVID-19 pandemic also boost the genome editing market growth. For instance, in March 2021, a team of researchers from the Nanyang Technological University developed a diagnostic test - VaNGuard (Variant Nucleotide Guard) based on CRISPR technology. This test can detect mutated SARS-CoV-2 strains, thereby increasing the adoption of CRISPR genome editing technology in the diagnostics arena.

Apart from this, continuous technological advancements in gene-editing tools are a major contributing factor for revenue generation in this market. For instance, in April 2021, researchers from Wyss Institute for Biologically Inspired Engineering at Harvard developed Retron Library Recombineering (RLR) - a new gene-editing tool that enabled the performance of millions of genetic experiments simultaneously, thereby providing better editing rates.

Ethical concerns related to genetic research is likely to hamper the market growth  

However, the major ethical issues, include the off-target mutation development, imbalance of the environment, and illegal usage of genome editing. The perspective of the general public toward gene editing is negative. Several scientists have advocated for the ban or prohibition of genome editing. This has created a lot of pressure on companies involved in genome editing, as they are unable to find suitable subjects to carry out clinical trials, resulting in the hindrance in the innovation. These factor will hamper the growth of the market in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has prompted key pharmaceutical and biotechnology companies, as well as players in the genome editing market, to invest in vaccine R&D. The rise in demand for vaccines and potential antiviral candidates has brought genome editing/engineering technologies to the forefront.

Compared to conventional diagnostic or treatment methods, molecular biology tools that include gene editing approaches, such as CRISPR-Cas12/13-based SHERLOCK, DETECTR, CARVER and PAC-MAN, ASO, antisense peptide nucleic acids, ribozymes, aptamers, and RNAi silencing therapies proved to be vital in COVID-19 outbreaks. From a shorter and easier diagnosis to more targeted virus detection and killing, these tools served as new generation diagnosis and treatment methods 

Segment Analysis

The CRISPR segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)     

CRISPR is expected to dominate the genome editing market during the forecast period owing to its wide range of advantages such as its tailor-made option specific to the patient’s mutations for the disease like cystic fibrosis etc. Moreover, the rise in funding, initiatives by the government to develop vaccines, medical technologies, drugs, devices are further propelling the growth of the genome editing market globally.

For instance, In May 2018, Feng Zhang's company Beam Therapeutics, new startup to develop CRISPR , officially came out with $87 million in series A funding and a mission to develop "precision genetic medicines" that use CRISPR technology to edit just one nucleotide base, or "letter," in the genome at a time. In 2018, Inscripta Colorado-based biotech acquired Solana Biosciences to ramp up the commercialisation of its gene-editing technology. Aiming to broaden access to CRISPR by offering new enzymes for free, and to boost CRISPR research by outfitting scientists with a full suite of tools. Furthermore, in 2017, Synthego and Thermo Fisher Scientific collaborated to manufacture and distribute synthetic guide RNA products for CRISPR genome engineering.

Geographical Analysis

North America region holds the largest market share of Global Genome Editing Market

The North America region occupied the largest market share of the global genome editing market in 2020, and estimated to dominate over the forecast period due to the strong growth trend in the pharmaceuticals and biotechnology industries. The North American meat industry, crop and cattle industry, equine, and canine breeding industry forms the largest consumer of genome editing services in the region. Additionally, genetic diseases, like cystic fibrosis, occur at a frequency of 1 in 2,500 birth in the United States.

Furthermore, the increasing number of patents awarded to U.S.-based key players has also accelerated the uptake of these tools in the country leading to significant market growth. For instance, Merck KGaA recently announced that two patents of the company have been approved in the U.S. for CRISPR gene-editing technologies. Thus these factors are driving the growth of the market in the region.

Competitive Landscape

The genome editing market is highly competitive with presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include GenScript USA Inc., Horizon Discovery Group plc, Integrated DNA Technologies Inc., Lonza Group Ltd, Merck & Co., New England Biolabs Inc., Origene Technologies Inc., Sangamo Biosciences Inc., Thermo Fisher Scientific Inc., Transposagen Biopharmaceuticals Inc., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Genome Editing Market globally. For instance, in February 2021, Caribou Biosciences, Inc. and AbbVie signed a license agreement for the research and development of CAR-T therapy. Abbvie gained rights to use Caribou's CRISPR genome editing technology under this agreement.

GenScript USA Inc.

Overview: Genscript Corporation is located in Piscataway, NJ, United States and is part of the Scientific Research and Development Services Industry. The company is a leading contract research organization (CRO) specialized in biological research and drug discovery/development services.

Product Portfolio:

EnGen® Lba Cas12a (Cpf1):  EnGen Lba Cas12a (Cpf1) is a programmable DNA endonuclease guided by a single guide RNA (gRNA). Targeting requires a gRNA complementary to the target site as well as a 5' TTTV protospacer adjacent motif (PAM) on the DNA strand opposite the target sequence. Cleavage by EnGen Lba Cas12a (Cpf1) occurs ~17 bases 3' of the PAM and leaves 5' overhanging ends.

Trending Topics

Genomics Market

Bio-Pharma Logistics Market

Genomics in Cancer Care Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest